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Diffuse large B-cell lymphoma (DLBCL) is the most common type of non-Hodgkin Lymphoma comprising of greater
than 30% of adult non-Hodgkin Lymphomas. DLBCL represents a diverse set of lymphomas, defined as diffuse
proliferation of large B lymphoid cells. Numerous cytogenetic studies including karyotypes and fluorescent in situ
hybridization (FISH), as well as morphological, biological, clinical, microarray and sequencing technologies have
attempted to categorize DLBCL into morphological variants, molecular and immunophenotypic subgroups, as well
as distinct disease entities. Despite such efforts, most lymphoma remains undistinguishable and falls into DLBCL,
not otherwise specified (DLBCL-NOS). The advent of microarray-based studies (chromosome, RNA, gene expression,
etc) has provided a plethora of high-resolution data that could potentially facilitate the finer classification of DLBCL.
This review covers the microarray data currently published for DLBCL. We will focus on these types of data; 1) array
based CGH; 2) classical CGH; and 3) gene expression profiling studies. The aims of this review were three-fold: (1) to
catalog chromosome loci that are present in at least 20% or more of distinct DLBCL subtypes; a detailed list of
gains and losses for different subtypes was generated in a table form to illustrate specific chromosome loci affected
in selected subtypes; (2) to determine common and distinct copy number alterations among the different subtypes
and based on this information, characteristic and similar chromosome loci for the different subtypes were depicted
in two separate chromosome ideograms; and, (3) to list re-classified subtypes and those that remained
indistinguishable after review of the microarray data. To the best of our knowledge, this is the first effort to compile
and review available literatures on microarray analysis data and their practical utility in classifying DLBCL subtypes.
Although conventional cytogenetic methods such as Karyotypes and FISH have played a major role in classification
schemes of lymphomas, better classification models are clearly needed to further understanding the biology,
disease outcome and therapeutic management of DLBCL. In summary, microarray data reviewed here can provide
better subtype specific classifications models for DLBCL.
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Diffuse large B-cell lymphoma (DLBCL) is the most fre-
quent non-Hodgkin lymphoma comprising of greater
than 30% of adult non-Hodgkin lymphomas in the West,
and an even higher percent in developing countries [1].
DLBCL has traditionally been defined as a diffuse prolif-
eration of lymphoid neoplasm in which the nucleus is
equal to or exceeds the size of a normal macrophage nu-
cleus [2]. It is clinically heterogeneous and includes a
wide spectrum of lymphoid neoplasms.
Many morphological, biological, cytogenetics and clin-
ical studies have attempted to subdivide DLBCL into
morphological variants, molecular, immunophenotypic
subgroups, and distinct disease entities. While progress
has been made in the recent years, many of the cases re-
main biologically heterogeneous [3,4]. In fact, the most
recent World Health Organization (WHO) classification
published in 2008 groups most of these lymphomas into
the category of DLBCL, not otherwise specified
(DLBCL-NOS) [4].
One recent microarray technology applied to distin-
guish between DLBCL subtypes is array based compara-
tive genomic hybridization (aCGH). Array-based CGH
provides high resolution genome wide measurement of
DNA copy number alterations highlighting patterns of
deletions and amplifications. An additional advantage
of array-based CGH is the assessment of allelic ratio or
loss of heterozygosity. Here, an assessment of the rela-
tive intensity for each of the alleles can be determined.
However; one limitation is the inability to detect balanced
chromosome translocations. Nonetheless, aCGH can
facilitate new construct classifiers for DLBCL subtypes.
Other key technology worth mentioning that may pro-
vide classification models for DLBCL include single
nucleotide polymorphism (SNP) arrays. Indeed, in re-
cent years a number of SNP array studies have been
reported that list characteristic SNP in hematolym-
phoid neoplasms [5-9].
An alternative microarray technology that has been
extensively used in the classification of DLBCL is gene
expression profiling. Studies using gene expression pro-
filing have stratified DLBCL into favorable and unfavor-
able groups i.e., the germinal center B-cell like (GCB)
and the activated B-cell like (ABC) DLBCL respectively
[1,10]. The ABC type expresses genes that are distinct-
ive of activated B-cells and plasma cells with a poor
clinical outcome (30% 5-year survival rate), whereas the
GCB subtype expresses a molecular signature of normal
germinal center B-cells with a more favorable overall sur-
vival (59% 5-year survival rate) [11-14]. Amplifications of
the REL loci, BCL-2 translocations and hypermutations
of the immunoglobulins loci are typical of the GCB-
DLBCL subtype [1,11,15]. In contrast, constitutive activa-
tion of the nuclear factor kB pathway is a distinctivefeature of both the ABC and primary mediastinal B-cell
lymphoma (PMBL) subtype [16-19]. A third type also
identified from others by molecular profiling is PMBL
with frequent amplifications at 2p and 9p corresponding
to JAK-2 and REL respectively with a 64% 5-year survival
rate [2,11,13,20,21]. Further studies with high resolution
array comparative genomic hybridization (aCGH) have
revealed recurrent copy number alterations (CNA), as
well as prognostic indicators in a number of DLBCL
subtypes [22-27], for example, in a recent high reso-
lution CGH study, CNA resistant to rituximab, cyclo-
phosphamide, doxorubicin, vincristine, and prednisone
(R-CHOP) therapy included amplifications of 1p36.13,
1q42.3, 3p21.31, 7q11.23 and 16p13.3, as well as losses
at 9p21.3 and 14p21.31 in DLBCL. Various reasons
have been proposed for the various CNA just men-
tioned above and immuno-chemoresistance. These in-
clude: faulty p53/INK/ARF functioning caused by
9p21.3 deletions seems to disrupt p53 induced apop-
tosis, up regulation of various target genes in the nu-
clear factor kB pathway due to copy number gain of
MAPKAPK3 at 3p21.31 leading to nuclear factor kB ac-
tivation and consequently resulting in high expression
of various apoptotic inhibiting genes [28-31] and copy
number gains at 16p13.3 resulting in overexpression of
ABCA3, which has been implicated as a likely cause of
drug resistance by driving the flow of drugs out of the
cell [32].
Despite these efforts to subdivide DLBCL, the relation-
ship between the different classification schemes has not
been adequately studied. In this review, we explored
CNA linked to well-defined WHO subtypes of DLBCL
and compared CNA across the various DLBCL subtypes.
Review of the literature
Diffuse large B-cell lymphoma, not otherwise specified
(NOS)
DLBCL NOS consists of all DLBCL cases that do not fit
into one of the other specific subtypes or disease entities
[1]. Since the NOS subgroup continues to exist as an in-
distinct set of DLBCL, the exact associated aberrations
are therefore more difficult to define. A study carried
out by Pasqualucci et al. [33] revealed aberrant somatic
hypermutations targeting multiple genetic loci including
PIMI, MYC, RHOH/TTF, and PAX. Moreover, abnormal-
ities of band region 3q27, t(14;18) translocations and
complex karyotypes are commonly seen in this subtype.
Array CGH and gene expression profiles identify molecular
subtypes
In 2008, Lenz et al. [2] analyzed 203 DLBCL samples by
high resolution array CGH and gene expression profile
to investigate the 3 molecular subtypes of DLBCL. Aber-
rations most characteristic of ABC DLBCL included
Table 1 Genomic Gains and Losses in ABC and GCB-
DLBCL Molecular Subtypes
Chromosome breakpoints GCB DLBCL ABC-DLBCL Reference












Key: G, genomic gain; L, loss of genetic material.
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duplications of 18q, deletion of INK4a/ARF tumor sup-
pressor locus on chromosome 9, and gain-amplification
of a 9-megabite (Mb) region on chromosome 19q. Tri-
somy 3 was the most frequent aberration seen in ABC
DLBCL (26%). In cases with trisomy 3, FOXP1 was the
most frequently up-regulated gene. Indeed, high FOXP1
expression is a characteristic finding of the ABC DLBCL
subtype and FOXP1 has been associated as an oncogene
[12,34,35]. In total, 38% of ABC DLBCL had an increase
in FOXP1 CNA compared to 4% and 3% for GCB
DLBCL and PMBL each. Another subtype specific lesion
for ABC DLBCL included NFKBIZ identified in a
chromosome 3 amplicon. It was detected in 9% of the
cases, while never identified in GCB DLBCL or PMBL.
NFKBIZ activates targets in the nuclear factor kB path-
way a hallmark for ABC DLBCL [36]. In terms of
the gain/amplification of 18q, which was significantly
more frequent in ABC DLBCL than the other molecular
subtypes, BCL-2 and NFATC1 were consistently up-
regulated by the gain/amplification of 18q. Another dis-
tinctive feature of ABC DLBCL compared to the other
two molecular subtypes was deletion of the INK4a/ARF
tumor suppressor locus; 30% of the ABC DLBCL cases
were deleted compared to 4% in GCB DLBCL and 6% in
PMBL. This locus encodes for three tumor suppressors:
CDKN2A (p16), CDKN2B (p15) and p14 ARF. For gain/
amplification of 19q, the overexpression of the SPIB gene
seems to play a more functional role in the pathogenesis
of ABC DLBCL. Recent work has revealed a transloca-
tion between SPIB and the immunoglobulin heavy chain
at 14q32 in ABC DLBCL [37]. Aberrations seen in GCB
DLBCL included amplification of the mir-17-92 micro-
RNA in the MIHG1 locus cluster on chromosome 13,
which has been shown to collaborate with MYC to trans-
form B-cells and to reduce apoptotic activity [38]. The
1.4-Mb amplified region on chromosome 13 was
detected 12.5% of the time in GCB DLBCL, rarely in
PMBL (3%), and not observed in ABC DLBCL. A gain of
a 7.6-Mb region on chromosome 12 revealed up-
regulation of MDM2, a negative regulator for the p53,
while deletion of the PTEN tumor suppressor gene on
chromosome 10, and amplification of the REL locus on
chromosome 2 were also more common in this molecu-
lar subtype. Interestingly, cases with PTEN deletion had a
t(14;18) translocation suggesting that loss of PTEN may
play a significant role in the pathogenesis of GCB DLBCL
with t(14;18). The most frequent chromosomal lesions
seen in PMBL included amplifications of a telomeric re-
gion of chromosome 9p, monosomy 10, and gain/ampli-
fication of chromosome 20p. It is unclear what genes in
these regions are functionally important in the pathogen-
esis of PMBL. Of note, genes that were more frequently
up-regulated in these regions were JAK-2 and T-cellinhibitor ligand PD-L2. These results confirm that
DLBCL can be confidently sub-grouped based on array
CGH results and gene expression profiles. In another
study by Tagawa et al. [22], array CGH was used to fur-
ther study the aberrations associated with ABC DLBCL
and GBC DLBCL. Based on their results, the ABC
DLBCL group was genomically characterized by more
frequent gains of 3q23-q28, 18q11.2-q23, 19q13.41-
q13.43 and loss of 6q22.31-q24.1 and 9p21.3, while the
GCB group was genomically characterized by more fre-
quent gains of 1q21.1-q23.3, 1q31.1-q42.13, 2p15-p16.1,
7q22.1-q36.2, and 12q13.1-q14. These results suggest
that ABC DLBCL and GCB DLBCL are genetically dis-
tinct from one another and arise from separate genetic
pathways [2] Table 1.Large B-cell lymphoma specified by site
Primary mediastinal large B-cell lymphoma
Primary Mediastinal Large B-cell Lymphoma (PMBL)
arises in the thymus from thymic B-cells that presents as
a mass in the mediastinum [1] and represent a distinct
entity within the germinal center (GC) derived high
grade DLBCL [39]. Although classified as a subtype of
DLBCL, it is noteworthy to mention that PMBL and
classical Hodgkin lymphoma (HL) share remarkably
similar molecular profiles, as well as certain clinical and
histological features [19,40]. In efforts to better define
PMBL, Palanisamy et al. [39] using classical CGH char-
acterized PMBL by whole chromosome gains of 12, 21,
22 and whole chromosome loses of 11, 13, and 18. Also,
frequent gains of 4q, 9q, 10p, 17p, 19p, 20q, 21q, 22q
and losses of 3q, 7p, 8q, 9p, 11p, 11q, 13q, 18p, 18q, Xp,
and Xq were seen in PMBL patients. Subsequent studies
used array based CGH to document amplification of
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studies reported amplifications to 9p and 2p involving
the REL locus on PMBL [21,40-42]. In 2007, Wessendorf
et al. [43] further outlined chromosomal aberrations in
PMBL using aCGH ( n= 37). Here, genomic gains of
9p24 (68%), 2p15 (51%), 7q22 (32%), 9q34 (32%), 12q
(30%) and 18q21 (22%) were reported. Interestingly, this
study also described 17 chromosome regions with gen-
omic losses in more than 10% of the cases. In terms of
clinical outcome, PMBL is now more favorable due to
intensive chemotherapy and radiation therapy [44]. As
stated previously, PMBL and cHD share very similar
molecular profiles, for example, frequent amplifications
at 9p24 have been reported in both PMBL and classical
HL; however, it is of interest to note that a study by Feys
and colleagues using cHD cell lines [45] reported dele-
tions of chromosome 15q26.2 encompassing RGMA and
CHD2, STAT6 up-regulation and deletion at 16q12.1
that were not found to occur in this current review of
PMBL. Further investigation is needed to see whether
these regions can be used to distinguish PMBL from
cHD.Large B-cell lymphoma of the bone (not listed as an entity
in 2008 WHO)
Large B-cell lymphoma of the bone (LBCLB) is a sub-
type of primary extra nodal DLBCL. It typically presents
in the longer bones, such as the humerus, tibia, pelvis,
spine or the femur. Patients present with pain, a palpable
mass or fractures. Complete remission is frequently
obtained with a combination of chemotherapy and
radiotherapy [9,46]. In 2010, Heyning et al. [46] used
array-CGH to study nine primary lymphoma of the
bone. Aberrations that were frequently seen included
loss of 1p35-36.3, 6q14-27, 14q32, 15q11-26, trisomy 7,
gain of 1q21-44, 6p21 and amplification of 2p16.1. Eight
of nine patients reached complete remission in this
study. These results support previously described GC-
like properties of LBCLB, particularly that of better clin-
ical outcome, 1q gain and 2p16.1 amplifications.DLBCL of the central nervous system
DLBCL of the CNS represents a subtype that comprises
all primary intracerebral or intraocular lymphomas [1].
Booman et al. reported genomic aberrations associated
with DLBCL of the CNS using an array-based CGH
(n= 9). The most common genomic aberrations seen in
this study were loss of 6p21.32-p25.2 (56%), 6q (56%),
17p12-p13.3 (56%) and gains of 1q21.3-q32.1 (33%),
12(44%), 15q12-q21.1 (22%), 7/7q (22%), 18q (22%)
and 19q13.12-q13.43 (22%) [47]. A similar study by
Montesinos et al. [48] reported similar findings. DLBCL
of the CNS is predominately of the molecular ABCsubtype, thus explaining the poor prognosis of this subset
of DLBCL [49].
Primary cutaneous LBCL, leg type
Based on the WHO classification scheme, there are
three types of primary cutaneous B-cell Lymphoma: leg
type (PCBCL), follicular center, and marginal zone. Leg
type is a DLBCL that presents with large transformed B-
cells that commonly arise in the leg at first [1]. In One
study [50], using array CGH and fluorescent in-situ
hybridization on 6 well characterized cases of PCBCL
reported distinct genomic aberrations. This study
showed recurrent gains of 1p36.33, 3p21.3, 7p, 7q11.21,
7q21.1, 11q13, 12q12-q13, 17q11.2, 17q21-22, 18q11.2,
18q21.1, 19q and losses to 9p21, 6q22-q23 and 17p11.2-
p12 in 50% or more of the cases. Among the chromo-
some regions with recurrent gains found in at least 33%
of the cases included: 1q25-q31, 1q41, 1q, 2p22, 2p12-
q11, 3p21-p25, 3q, 7q, 8q24, 9p12-q21, 11q, 12p11,
12q13-q15, 12q32, 16q23, 17q11-q12, 17q21, 18q,
19q13, 20q13,22q11 and 22q13. Similarly, recurrent
losses in 33% of the cases were 1p36.31, 1p31-p32, 1p13,
4q, 6q, 8p, 8q11, 9p11, 14q, Xq13 and Xq25. One of the
most frequent aberrations mentioned in this study was
the loss of 9p21(83%). Of the six patients with 9p21 de-
letion, all died in this study. Similar observations have
reported deletions to 9p21.3, for example, one study
identified 9p21 loss in eight of 12 patients with PCBCL
[51]. Of the seven patients that died in this study, five
cases had a deletion at 9p21. This may suggests that loss
of this region has important clinical significance. In a re-
cent study, it was revealed that the incidence of 9p21
loss was more prevalent in the ABC molecular subtype
compared to the GC DLBCL subtype, demonstrating a
poor clinical outcome for the loss of 9p21 [23]. Indeed,
PCBCL is associated with the ABC DLBCL molecular
subtype and requires therapy intensification [50].
Large B-cell lymphoma specified by histology, phenotype,
or genotype
T-cell Histiocyte-rich B-cell lymphoma
T-cell/histiocyte-rich B-cell lymphoma (T/HR) has been
categorized as a DLBCL, but it had been done with
much controversy due to the ambiguous presentation of
the malignancy. T/HR LBCL is distinguished by a few
scattered, large, atypical B-cells surrounded by a large
quantity of T-cells and scattered histiocytes [1]. Classical
CGH studies by Franke et al. [52] revealed most com-
mon gains of 4q13q38,18q21, Xq and Xp21-p11, as well
as recurrent losses 17p. Most frequent CNA in this
above report were Xq12-13 (58%), 4q25-q26 (41%),
Xp11-21 (29%), 18q21 and 17p (24% each). Molecular
profiles have identified most T/HR DLBCL cases to a
subgroup of DLBCL distinguished by a “host response”
Tirado et al. Journal of Hematology & Oncology 2012, 5:54 Page 5 of 12
http://www.jhoonline.org/content/5/1/54with an adverse clinical outcome [53]. To the best of our
knowledge, there is no array based CGH reports on this
entity.
De novo, CD5+ large B-cell lymphoma
DLBCL expresses a variety of B-cell surface markers in-
cluding CD5 in approximately 10% of cases [54]. Previ-
ous studies have reported a worst clinical outcome for
CD5+ DLBCL compared to CD5- DLBCL [55,56]. In a
genome wide array based CGH (n = 25), Tagawa et al.
[57] identified genomic gains in more than 30% of the
case in the following band regions: 1q23.1, 3q12.1,
3q27.3, 11q23.3, 11q24.3, 12p12.1, 12q13.3, 12q14.1,
12q15, 13q21.32, 13q32.3, 16p13.3, 18q21.1, 18q22.3,
19q13.33, 19q13.41, 19q13.43. Likewise, genomic losses
were detected in 1p36.32, 6q21, 8p23.3, 9p21.3 and
17p13.1. Of note, by concentrating on the gain of
13q21-34 and loss of 1p34-36, Tagawa et al. was also
able to recognize prognostically distinct subgroups
within the CD5+ DLBCL subset. Moreover, in a separate
study [23], Tagawa et al. identified 3q23-3q28 (31%),
6q22.31-q24.1 (44%) and 9p21.3 (50%) in high frequency
for CD5+ DLBCL. When comparing CNA and clinical
outcome, this latter study demonstrated 9p21 marked
the most aggressive cases. In fact, Kreisel et al. [27]
showed 9p21.3 band region as chemoresistant in
DLBCL.
Large B-cell lymphoma (LBCL) associated with epstein-
barr virus and/or kaposi sarcoma–associated herpesvirus/
human herpesvirus 8
DLBCL associated with chronic inflammation
Diffuse large B-cell lymphoma associated with chronic
inflammation (CI) is a DLBCL associated with long last-
ing inflammation that is associated with EBV+. In most
cases, this subtype of DLBCL develops in small body
cavities and narrow spaces [1,10].
Pyothorax-associated lymphoma
Pyothorax-associated Lymphoma (PAL) develops in the
pleural cavity of patients with a history of long-standing
pyothorax [1]. Most reported cases of PAL have oc-
curred in Japan, with few cases reported in western
countries. Immunoglobulin genes in PAL are usually
clonally rearranged and usually TP53 mutations can be
seen [58,59]. PAL is usually a precursor to DLBCL asso-
ciated with chronic inflammation [10]. Few studies have
attempted to define distinct CGH profiles for the PAL
subtype. Using classical CGH analysis, Yamato et al. [60]
showed the amplification of the 8q24 band region in 7
PAL cases. Amplification was later confirmed in four
cases by southern blot analysis. Another separate study
reported an over-expression of the interferon alpha-inducible protein 27, IFI27 [61]. By cytogenetic analysis,
one study reported complex karyotypes but no common
abnormality was reported [62].Plasmablastic lymphoma
Plasmablastic lymphoma (PL) is a scattered proliferation
of large neoplastic cells that have the immunophenotype
of plasma cells but resemble B-immunoblasts. It was ori-
ginally described in the oral cavity but may occur in
other extra-nodal sites [1]. In 2009, an array-based CGH
conducted by Chang et al. [63] reported gains (>40%) of
1p36.11-1p36.33, 1p34.1-1p36.13, 1q21.1-1q23.1, 7p21.3-
7p23 (38%), 7q11.2-7q11.23, 8q24.3 (25%), 10p12 (23%),
11q12-11q13.2, 14q32 (31%), 16p13.2-p13.3 (38%),
16q24 (38%), 17p13 (38%), 20q11.1-q11.23 (38%) and
22q12.2-22q13.3 in PL, while genetic losses were more
diverse. However, only 1p35.1-1p36.12, 1q21.1-1q23.1
and 1p36.11-1p36.33 were unique to PL when compared
with DLBCL (AIDS related and non-AIDS related) and
plasma cell myeloma. The clinical outcome for these
patients is poor [64].Primary effusion lymphoma
Primary Effusion Lymphoma (PEL) is another rare sub-
type of DLBCL that presents as an extravascular collec-
tion of fluids with no identifiable tumor mass. It is
associated with the Human Herpes Virus 8 (HHV8 +),
the Kaposi sarcoma herpes virus (KSHV) and carries a
poor clinical outcome in PEL patients [1,65,66]. Very lit-
tle is known about the genetic aberrations associated
with this malignancy. A recent array CGH study revealed
gains of 1q21-41 (47%), 4q28.3-35 (29%), 7q (58%), 8q
(63%), 11 (32%), 12 (61%), 17q (29%), 19p (34%), 20q
(34%) and losses of 4q (32%), 11q25 (29%) and 14q32
(63%) [67]. In an earlier study using classical CGH
(n = 5), Ohshima et al. [68] identified gains of 3q13-q27,
8q24, 8, 10q21-23 and Yq in HHV8 negative PEL cases.Unclassifiable types
LBCL with features intermediate between DLBCL and Burkitt
lymphoma
Large B-cell lymphoma with features intermediate be-
tween DLBCL and Burkitt lymphoma (INT) is an aggres-
sive lymphoma that has overlapping features between
DLBCL and Burkitt lymphoma. Approximately 35-50%
of INT cases have MYC rearrangements [69,70] with a
concurrent BCL-2 translocation (“double-hit lymphoma”)
in approximately 15% of cases. A limited number of array
based CGH studies are available. In 2006, Hummel et al.
[69] using aCGH reported most of these cases with a
high chromosomal complexity with a score of 6 or more
abnormalities with a MYC rearrangement.
Table 2 Array CGH data of gains and losses for the various DLBCL Subtypes
Chromosome breakpoints PMBL Bone CNS Leg type T/HR CD5+ PAL PL PEL
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1q22 + + + + +
1q23 + + + + + +
1q24-q25 + + + +
1q31-q32 + + + +
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Table 2 Array CGH data of gains and losses for the various DLBCL Subtypes (Continued)
7q22 + + + +
7q31 + + +
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Key: +, Gain; -, Loss; PMBL, Primary mediastinal large B-cell lymphoma; Bone, Primary large B-cell lymphoma of bone; CNS, DLBCL of the central nervous system;
Leg type, Primary cutaneous large B-cell lymphoma leg type; T/HR, T-cell/histiocyte-rich B-cell lymphoma (no aCGH data available); CD5+ , De novo CD5 large
B-cell lymphoma; PAL, Pyothorax-associated lymphoma; PL, Plasmablastic lymphoma; PEL, primary effusion lymphoma. Amplification of 8q24 listed here in PAL
was detected by classical CGH and southern blot analysis.
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Intravascular large B-cell lymphoma
Intravascular Large B-cell lymphoma (ILBCL) is differen-
tiated by localization of atypical lymphomatous cells
within smaller vessels and capillaries [1,71]. It is a rare, ag-
gressive extra nodal B-cell lymphoma that is recognized in
the 2008 WHO classification as a subset of DLBCL.
ILBCL is known as the great imitator due to the fact that
it presents with a broad spectrum of nonspecific symp-
toms with no distinct array CGH profile [10].Anaplastic lymphoma kinase-positive LBCL
Anaplastic large cell lymphoma with expression of the
anaplastic kinase protein is a rare neoplasm of ALK-
positive monomorphic large B-cells with immunoblastic
or plasmablastic morphology. The only chromosome ab-
erration associated with this disorder is the involvement
of the ALK gene on chromosome 2. The gene is usually
involved with the following translocations: t(2; 17)(p23;
q23) or t(2:5)(p23;q35). This type of lymphoma is a rare
entity constituting only less than 1% of DLBCL cases.
Thus, no substantial CGH data is available [1,10]. Patients
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EBV+DLBCL of the elderly
Epstein-Barr virus-positive DLBCL of the elderly is a
newly recognized subtype of DLBCL by the WHO classi-
fication (2008) which presents as an EBV+ clonal B-cell
proliferation usually in patients over 50 years [1,73,74].
EBV+DLBCL is such a new classification of DLBCL
that there is not sufficient CGH array data to create aFigure 1 Panel A shows an ideogram spectrum for unique gains and
gains are provided on the right hand side of each chromosome, while gen
ideogram. Each category is represented by a different color coded bar as il
subtypes. Commonalities were highlighted if three or more subtypes had agenomic profile or distinctive cytogenetic pattern for
such malignancy [75].
Large B-cell lymphoma arising in HHV8+ multicentric
castleman disease
LBCL occurring in HHV8+ associated multicentric castle-
man disease is characterized by monoclonal proliferation of
HHV8+ lymphoid cells in the presence of multicentric cas-
tleman disease [1]. It is an aggressive disorder with no infor-
mation about the cytogenetics or CGH profiles [1,76].losses for the various DLBCL subtypes. Chromosome band region
etic losses are shown on the left hand side of each chromosome
lustrated in the schematic. Panel B illustrates common CNA for all
CNA at that particular band region.
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Lymphomatoid Granulomatosis (LG) is an angiocentric
and angiodestructive proliferative B-cell neoplasm that
involves extra-nodal sites. LG is composed of malignant
B-cells that are Epstein-Barr virus-positive combined
with reactive T-cells. Clinical outcome is variable and
depended on the quantity of large B-cells [1]. The major-
ity of studies on LG have failed to identify unique
chromosomal aberrations; however, a study by Godde-
Salz et al. [77] reported few consistent chromosome
aberrations including trisomy of chromosome 3 and 5
along with duplications of the X chromosome.
LBCL with features intermediate between DLBCL and
Hodgkin lymphoma
This type of lymphoma is characterized by clinical and
morphological features that overlap between DLBCL,
particularly primary mediastinal large B-cell lymphoma,
and classic Hodgkin lymphoma. Only limited cases of
LBCL with features intermediate between DLBCL and
Hodgkin lymphoma have been studied.
The table below summarizes genomic gains and losses
for the various DLBCL subtypes, Table 2-, Figure 1-.
Conclusions
In this review, we explored associated copy number
alterations (CNA) in 2008 WHO-defined DLBCL sub-
types by array CGH. Certain chromosomal aberrations
that were significantly more frequent in a particular
DLBCL subtype than in the others, and some of these
aberrations were associated with clinical outcome. Fol-
lowing our review of aCGH microarray studies, a num-
ber of subsets were re-classified, for example, unique
chromosome loci were identified in the following sub-
types: PMBL, gain at 2p15, 9p24, 9q34, Xp11.4-21,
Xq24-26; Large B-cell lymphoma of the bone, gain at
2p16, 6p21 and loss at 15q15-q26; DLBCL of the CNS,
loss at 6p21-25,17p12-13; Leg type DLBCL, gain at
2p22, 2p12, 3p21-25, 3q28-29, 9p12-21,16q23,22q11and
loss at 4q, 8p11,14q, Xq13-25; CD5+ DLBCL, gain at
13q21-34; Plasmablastic lymphoma, gain at 10p12,
14q32, 16q24,17p12-13 and primary effusion lymphoma
with gains at 4q28-35, 8q11.2-23.1, 11p, 17q23-24,
19p13 and loss at 11q24-25. However, despite these
efforts, there is still a number of unclassifiable DLBCL
subtypes post-microarray studies. Among these include
intravascular LBCL, EBV+DLBCL of the elderly, large
B-cell lymphoma arising in HHV8+ multicentric Castle-
man disease, Lymphomatoid granulomatosis, LBCL with
features intermediate between DLBCL and HL and PAL.
Several reasons for this may include: a limited number
of study cases, uncommon disease entities and a com-
paratively small number of publicly available aCGH
datasets. Therefore, future studies should aim on thecopy number alterations in newly defined uncommon
large B-cell lymphoma entities, such as EBV+DLBCL of
the elderly, ALK positive DLBCL and LBCL arising in
HHV8-associated multicentric castleman disease. More-
over, as more array based CGH datasets become publicly
available, meta-analysis studies should further characterize
DLBCL subsets. Likewise, given the large collective num-
ber of gene expression datasets for DLBCL subtypes and
using novel computational methods such as hidden Mar-
kov models to predict CNA from gene expression profil-
ing [78] should significantly improve our understanding of
the biology, clinical outcome and therapeutic management
of DLBCL. Moving forward, microarray analysis should be
used in an integrative approach using aCGH, gene expres-
sion profiles, SNP arrays and next generation sequencing
techniques to better categorize DLBCL subtypes.
In short, our analysis provides a rich starting point for
future investigations into the molecular pathogenesis of
DLBCL. This review revealed oncogenic pathways that
are used differentially by the DLBCL subtypes, reinfor-
cing the view that they represent pathogenetically dis-
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